|
|
||||||||
The Journal of Neurophysiology Vol. 85 No. 5 May 2001, pp. 2008-2016
Copyright ©2001 by the American Physiological Society
1Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg 194223, Russia; and 2Veterans Administration Medical Center Sepulveda and Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, North Hills, California 91343
| |
ABSTRACT |
|---|
|
|
|---|
Kiyashchenko, Lyudmila I., Boris Y. Mileykovskiy, Yuan-Y. Lai, and Jerome M. Siegel. Increased and Decreased Muscle Tone With Orexin (Hypocretin) Microinjections in the Locus Coeruleus and Pontine Inhibitory Area. J. Neurophysiol. 85: 2008-2016, 2001. Orexin-A (OX-A) and orexin-B (OX-B) (hypocretin 1 and hypocretin 2) are synthesized in neurons of the perifornical, dorsomedial, lateral, and posterior hypothalamus. The locus coeruleus (LC) receives the densest extrahypothalamic projections of the orexin (OX) system. Recent evidence suggests that descending projections of the LC have a facilitatory role in the regulation of muscle tone. The pontine inhibitory area (PIA), located ventral to LC, receives a moderate OX projection and participates in the suppression of muscle tone in rapid-eye-movement sleep. We have examined the role of OX-A and -B in muscle-tone control using microinjections (0.1 µM to 1 mM, 0.2 µl) into the LC and PIA in decerebrate rats. OX-A and -B microinjections into the LC produced ipsi- or bilateral hindlimb muscle-tone facilitation. The activity of LC units was correlated with the extent of hindlimb muscle-tone facilitation after OX microinjections (100 µM, 1 µl) into fourth ventricle. Microinjections of OX-A and -B into the PIA produced muscle-tone inhibition. We did not observe any significant difference in the effect of OX-A and -B on muscle tone at either site. Our data suggest that OX release activates LC units and increases noradrenergic tonus in the CNS. Moreover, OX-A and -B may also regulate the activity of pontine cholinoceptive and cholinergic neurons participating in muscle-tone suppression. Loss of OX function may therefore disturb both facilitatory and inhibitory motor processes.
| |
INTRODUCTION |
|---|
|
|
|---|
Sakurai and co-authors
(1998)
identified two novel neuropeptides, the orexins (OXs),
which are synthesized in neurons of the lateral and posterior
hypothalamus. These neuropeptides are identical to the hypocretins
previously described by De Lecea and collaborators (1998)
. Axons of OX cells have a widespread distribution
throughout the adult brain in areas outside the hypothalamus, including
the cerebral cortex, medial portions of the thalamus, subfornical organ, area postrema, hippocampus, amygdala, indusium griseum, locus
coeruleus (LC), and raphe nuclei (Date et al. 1999
;
De Lecea et al. 1998
; Horvath et al.
1999
; Lubkin and Stricker-Krongrad 1998
;
Nambu et al. 1999
; Peyron et al. 1998
).
Initially it was proposed that the OXs participate in the control of
feeding behavior as neuromodulators or neurotransmitters (Lubkin
and Stricker-Krongrad 1998
; Sweet et al. 1999
;
Takahashi et al. 1999
), but this function has been
questioned (Edwards et al. 1999
; Ida et al.
1999
; Taheri et al. 1999
). Current evidence
indicates that OX-A and -B are involved in the CNS regulation of
endocrine and autonomic functions, glucose and energy homeostasis,
reproduction, and the sleep-wakefulness cycle (Hagan et al.
1999
; Kilduff and Peyron 2000
; Lubkin and Stricker-Krongrad 1998
; Moriguchi et al. 1999
;
Pu et al. 1998
; Samson et al. 1999
;
Siegel 1999
; Takahashi et al.
1999
).
Cataplexy, the sudden loss of muscle tone occurring in narcoleptic
humans and animals, is triggered by the sudden onset of certain strong
emotions and by particular kinds of motor activity. A mutation in the
hypocretin (orexin) receptor 2 gene is the genetic cause of canine
narcolepsy (Lin et al. 1999
). Most human narcoleptics have reduced levels of hypocretin-1 in their cerebrospinal fluid (Nishino et al. 2000
). Mice with a null mutation of the
prepro-orexin show aspects of narcolepsy (Chemelli et al.
1999
). Wu and co-authors (1999)
reported that LC
units invariably cease their activity before and during cataplectic
attacks in narcoleptic dogs. The LC has been shown to have a role in
muscle-tone facilitation in studies in decerebrate cats
(D'Ascanio et al. 1989
; Stampacchia et al.
1987
). The LC receives the densest extrahypothalamic
projections of the OX system (Hagan et al. 1999
;
Horvath et al. 1999
; Nambu et al. 1999
;
Peyron et al. 1998
). OX-A and -B applications excite LC
units in the in vitro slice preparation (Hagan et al.
1999
; Horvath et al. 1999
). These findings
suggest that OX release in the LC could have a role in muscle-tone control.
The pontine inhibitory area (PIA) elicits muscle-tone suppression with
cholinergic (George et al. 1964
; Takakusaki et
al. 1994
) and glutamatergic (Lai and Siegel
1990a
) stimulation. Lesions of this region produce
rapid-eye-movement (REM) sleep without muscle atonia (Henley and
Morrison 1974
; Jouvet and Delorme 1965
). The
middle portion of the pontine reticular nucleus, oral part, and
subcoeruleus region from which these effects were elicited, termed the
PIA, has a low to moderate concentration of OX axons (Peyron et
al. 1998
). Thus OX release in the PIA might also affect muscle
tone. The current study was undertaken to determine the effects of OX
microinjections into the LC and PIA on the regulation of muscle tone
and motor activity.
| |
METHODS |
|---|
|
|
|---|
All procedures were approved by the Animal Studies Committee of
the Sepulveda Veterans Affairs Medical Center/UCLA in accordance with
U.S. Public Health Service guidelines. Seventy-two Wistar rats
(250-300 g) were operated on, and 48 of them showed muscle rigidity
and were used in our experiments. We used decerebrate rats with
postdecerebrate electromyographic (EMG) levels from 20 to 300 µV in
our studies (Lai and Siegel 1988
, 1990a
,b
, 1991
). Animals with EMG level less than 20 µV or showing unilateral muscle rigidity were excluded from this study.
Surgery
Animals were anesthetized with halothane (Fluothane) followed by
ketamine HCL (Ketalar, 70 mg/kg ip) for cannulation of the trachea and
decerebration. Two holes (diameter, 2.0 mm) were symmetrically drilled
over the skull above the LC nuclei and PIA (Hajnik et al.
2000
) at 9.2 mm posterior to bregma and 1.3 mm lateral to midline for microinjections and LC unit recordings. Then two
rectangular holes were cut in each parietal bone in preparation for
decerebration. The transverse anterior and posterior borders of these
holes were located 1 and 5 mm posterior to bregma with longitudinal
sagittal borders 0.5 mm from midline. Precollicular-postmammillary
decerebration was carried out 4.0-5.0 mm posterior to bregma using a
stainless steel spatula, taking care not to injure the sagittal vein.
Excess fluid was aspirated by syringe and absorbed with Gelfoam
(Upjohn). Guide cannulae, 0.6-mm diam, were fixed on the skull bone for OX-A, OX-B, saline, and clonidine microinjections into the fourth ventricle. Coordinates of all structures were based on the rat brain
atlas (Paxinos and Watson 1997
).
Rectal temperature was continuously monitored with an electrical thermometer (Model BAT-12, Physitemp) and maintained between 37 and 38°C with a Heat Therapy Pump (Model NO. TP-500, Gaymar Industries). Experiments were begun when bilateral postdecerebrate muscle rigidity appeared (0.5-3 h).
Microinjections
The animals were divided into four groups: the first group (n = 17) was used for OX-A microinjections into the LC and PIA, the second group (n = 19) for OX-B microinjections into these structures, the third group (n = 4) for control saline microinjections into the LC and PIA, and the fourth group (n = 8) for saline, OX-A, OX-B, and clonidine microinjections into fourth ventricle during LC unit recording.
In each experiment, four injection sites (2 in the LC and 2 in the PIA) were sequentially tested each with one microinjection. Sites were tested in random order. Subsequent microinjections were performed when muscle tone returned to background. The microinjections into the LC and PIA consisted of 0.2 µl administrated at a rate 10 nl/s. OX-A and -B (Peptide Institute, Osaka, Japan) were dissolved in distilled water to create stock solution (1 mM). Stock solution was stored at 4°C for a maximum of 3 wk. Before experiments, stock solution was dissolved in 0.9% saline to get 0.1, 0.2, 1, and 100 µM concentrations of OX-A and -B.
The response of LC units to OX-A and -B microinjections (100 µM, 1 µl) and clonidine hydrochloride (Sigma) microinjections (20 mM, 1.0 µl, PH 4.0) was determined. Clonidine was dissolved in saline. The
microinjections into the fourth ventricle were performed via guide
cannulae with outside diameter of 0.6 mm. All injections were performed
using a 1-µl Hamilton microsyringe and an injecting cannula with
outside diameter of 0.25 mm. A previous study (Hajnik et al.
2000
) has shown that the majority of inhibitory sites were
located in the oral pontine reticular nucleus in the region rostral to
the LC. Therefore the cannula did not damage LC units during
microinjections performed into the ventral pons.
Stimulation and recording
Constant-current square-wave pulses (0.2 ms, 30 Hz, 50-100
µA, continuous stimulation for 5-10 s) were delivered using an S88
stimulator (Grass Instruments) coupled to a Grass SIU5 stimulus isolation unit. The areas of the pontine reticular formation producing hindlimb muscle-tone inhibition were located by stereotaxic coordinates (Hajnik et al. 2000
) and confirmed with electrical
stimulation via a tungsten monopolar microelectrode (A-M Systems). The
LC was located by stereotaxic coordinates. OX-A, OX-B, or saline was
microinjected into the identified areas.
EMGs were recorded from the neck (splenius muscle) and hindlimbs
(gastrocnemius and tibialis anterior muscles) bilaterally with
stainless steel wires and were amplified using a Grass polygraph (Model
78D). We chose these ankle extensors and flexors because LC electrical
stimulation has been shown to excite spinal motoneurons innervating
these muscles (Fung et al. 1987
) and facilitate their muscle tone (Lai et al. 1989
). Extracellular unit
recordings were performed using tungsten monopolar microelectrodes (A-M
Systems). Spikes were amplified with a Model 1700 A-M Systems
amplifier. Unit pulses and EMGs were recorded on a PC using the
1401plus interface and Spike2 program (Cambridge Electronic Design,
Cambridge, UK). The rate of digitization was 372 Hz for EMG and 21 kHz
for unit activity.
Identification of LC cells
Cells were classified as noradrenergic using the criteria
reported for LC cells in rats and cats (Aston-Jones and Bloom
1986
; Foote et al. 1980
; Guyenet
1980
). These criteria include slow and regular firing,
long-duration (>2 ms) action potentials, suppression of firing by
intraventricular administration of the alpha2-agonist clonidine, fast
activation followed by inhibition in response to a pinch applied to
hindlimb paw, and histological location within the LC tyrosine
hydroxylase-positive cell cluster.
Histology
Cathodal current (0.1-0.2 mA, 4-6 s) was passed through the
microelectrodes at the end of each track. The location of recorded neurons was determined by using the track made by the microelectrode, depth of the marking lesion, and depth measurements on the microdrive. Rats were deeply anesthetized with pentobarbital (70 mg/kg ip) and
perfused transcardially with 0.01 M phosphate-buffered saline (PBS,
pH = 7.4) followed by 4% paraformaldehyde in 0.1 M PBS. Brains
were removed, cut into 60-µm-thick sections, and immunostained for
tyrosine hydroxylase (TH). Sections were rinsed three times in 0.05 M
Trizma-buffered saline (pH = 7.4) followed by a 24-h incubation in
a 1/400 dilution of primary mouse antiserum to TH (Chemicon, Temecula,
CA) with a solution of 2% normal goat serum in 0.05 M Trizma-buffered
saline (pH 7.4) at 4°C. This was followed by a 2-h incubation in a
1/200 dilution of biotinylated goat anti-mouse IgG (Vector, Burlingame,
CA). The tissue was then incubated for 2 h with the avidin-biotin
complex (Vector). Each incubation was followed by three rinses.
Dilutions and rinses were prepared with 2% normal goat serum in 0.05 M
Trizma-buffered saline. The sections were then treated with 0.05%
solution of 3,3' diaminobenzidine and 0.01% hydrogen peroxide. The
electrode tracks and the TH-positive cells were identified on a Nikon
microscope and plotted with a Neurolucida interface according to the
rat brain atlas (Paxinos and Watson 1997
).
Data analysis
The latency of muscle-tone changes was measured from the start of the microinjection to either a 30% increase or a 30% decrease in nonintegrated EMG amplitude compared with baseline. The duration was calculated from the time of onset of a sustained increase or decrease in muscle tone until the return to baseline levels. The latencies and durations were averaged for right and left hindlimbs for microinjections that produced bilateral muscle-tone variations. The latencies and durations of muscle-tone changes were analyzed by ANOVA. Unit firing rates were analyzed by Wilcoxon matched-pairs test. The average unit firing rates were calculated for 10 s before and after OX microinjections when sustained muscle-tone facilitation was observed.
Regression analysis was used for estimating the correlation between
changes of LC unit firing rate and integrated ipsilateral gastrocnemius
EMG. LC unit excitation and inhibition predominantly affect extensor
tonus in the ipsilateral limbs (Andre et al. 1995
; Pompeiano 1998
). The changes of integrated EMG and
firing rate were calculated in percent of baseline level. Digital EMG
integration was performed with 10-s epochs. All average values are
means ± SE.
| |
RESULTS |
|---|
|
|
|---|
OX-A and -B microinjections in the vicinity of LC
Thirty-four OX-A microinjections (0.2 µM to 1 mM, 0.2 µl) were performed in the vicinity of LC (Fig. 1) in 17 decerebrate rats. Sixteen microinjection sites located in the LC produced bilateral muscle-tone facilitation (Fig. 2A), and 12 sites located similarly evoked ipsilateral muscle-tone facilitation (Fig. 2B). Four OX-A microinjections into the subcoeruleus nucleus, alpha part (SubCA) inhibited muscle tone bilaterally (Fig. 2C) and two microinjections into the SubCA produced ipsilateral muscle-tone inhibition.
|
|
Similar doses of OX-B were injected into 38 sites in the vicinity of LC in 19 decerebrate rats. The location of OX-B microinjection sites was similar to these represented in Fig. 1. Eighteen microinjections into the LC produced bilateral muscle-tone facilitation, and 11 sites evoked ipsilateral muscle-tone facilitation. Five OX-B microinjections into the SubCA decreased muscle tone bilaterally, two produced ipsilateral muscle-tone inhibition, and two microinjections were ineffective.
Latency and duration of muscle-tone facilitation
OX-A and -B microinjections in the vicinity of LC increased hindlimb muscle rigidity in a dose-dependent manner. The response thresholds were between 0.1 and 0.2 µM for OX-A and -B. The latency of muscle-tone facilitation (Fig. 3A) changed from 200 ± 13 s (n = 7, 0.2 µM) to 66 ± 8 s (n = 7, 1 mM) for OX-A and from 182 ± 17 s (n = 7, 0.2 µM) to 63 ± 7 s (n = 7, 1 mM) for OX-B. The duration of muscle-tone facilitation also had a dose-dependent time course (Fig. 3B) and ranged from 530 ± 67 s (n = 7, 0.2 µM) to 2211 ± 208 s (n = 7, 1 mM) for OX-A and from 491 ± 40 s (n = 7, 0.2 µM) to 2116 ± 285 s (n = 7, 1 mM) for OX-B. We did not observe significant differences between the action of equimolar concentrations of OX-A and -B on hindlimb muscle tone (for latency: F0.2 µM = 0.72, P > 0.5; F1 µM = 0.36, P > 0.75; F100 µM = 0.08, P > 0.85; F1 mM = 0.13, P > 0.75; df = 1, 12; for duration: F0.2 µM = 0.29, P > 0.75; F1 µM = 0.46, P > 0.75; F100 µM = 0.08, P > 0.8; F1 mM = 0.07, P > 0.8; df =1, 12). Saline microinjections (n = 6) into the vicinity of LC in four control rats did not produce muscle-tone facilitation within the 1-h postinjection observation period.
|
OX-A and -B microinjections into the PIA
Thirty-four OX-A microinjections (0.2 µM to 1 mM, 0.2 µl) were performed into the PIA sites (Fig. 1) identified previously by electrical stimulation (50-100 µA) in 17 rats. Twenty microinjection sites produced bilateral muscle-tone inhibition (Fig. 4A). Eight sites evoked ipsilateral hindlimb muscle-tone inhibition with contralateral muscle-tone facilitation (Fig. 4B), and six sites induced contralateral muscle-tone inhibition (Fig. 4C).
|
OX-B microinjections were performed into 38 identified inhibitory sites of the PIA in 19 rats. Twenty-two microinjection sites produced bilateral muscle-tone inhibition, 10 sites induced ipsilateral muscle-tone inhibition with contralateral muscle-tone facilitation, and 6 sites evoked contralateral muscle-tone inhibition.
Latency and duration of muscle-tone inhibition
The latency of bilateral muscle-tone inhibition produced by OX-A and -B microinjections had a dose-dependent time course and changed from 225 ± 28 s (n = 5, 0.2 µM) to 52 ± 8 s (n = 5, 1 mM) for OX-A and from 221 ± 32 s (n = 5, 0.2 µM) to 57 ± 8 s (n = 5, 1 mM) for OX-B (Fig. 5A). The response thresholds for OX-A and -B were between 0.1 and 0.2 µM. The duration of muscle-tone inhibition (Fig. 5B) changed from 208 ± 15 s (n = 5, 0.2 µM) to 965 ± 87 s (n = 5, 1 mM) for OX-A and from 179 ± 19 s (n = 5, 0.2 µM) to 810 ± 54 s (n = 5, 1 mM) for OX-B. We did not observe significant differences between the action of equimolar concentrations of OX-A and -B in the PIA (for latency: F0.2 µM = 0.01, P > 0.9; F1 µM = 0.01, P > 0.9; F100 µM = 0.90, P > 0.5; F1 mM = 0.52, P > 0.5; df = 1, 8; for duration: F0.2 µM = 1.50, P > 0.5; F1µM = 0.69, P > 0.5; F100µM = 0.20, P > 0.75; F1mM = 2.26, P > 0.25; df = 1, 8). Control microinjections of saline at the same sites (n = 6) did not produce hindlimb muscle-tone inhibition in three control rats.
|
LC unit activity after OX-A and -B microinjections into the fourth ventricle
Microinjections of OX-A and -B into the fourth ventricle between the LC nuclei produced muscle-tone facilitation in eight rats with postdecerebrate muscle-tone rigidity. We used these microinjections to determine if LC units participate in the muscle-tone facilitation induced by OX-A and -B.
Eighteen recorded neurons met the criteria for noradrenergic cells (Fig. 6). These neurons showed a regular (4.7 ± 2.0 spike/s, n = 18) firing rate when hindlimb rigidity was observed and had an average spike duration of 2.4 ± 0.1 ms (n = 18). Pinching of the hindlimb paw on either side evoked an initial (0.3-0.8 s) burst of activity following by inhibition (lasting 1-3 s). Immunohistochemistry confirmed that these cells were located in TH-positive regions. Clonidine injections in the fourth ventricle performed after OX-A and -B microinjections inhibited activity in all putative noradrenergic neurons and suppressed muscle tone. Complete inhibition of LC unit activity and muscle-tone suppression after clonidine microinjection occurred at average latencies 28.0 ± 1.7 s (n = 18) and 42.2 ± 3.9 s (n = 18), respectively. Unit activity and muscle tone returned in parallel to the baseline level by 52.9 ± 2.0 min (n = 18) after clonidine microinjections.
|
Ten LC units were observed during OX-A microinjections (100 µM, 1 µl) into the fourth ventricle. The discharge frequency of nine of these cells was increased by an average 187 ± 24% (n = 9, T = 0, P < 0.01) compared with the baseline and the magnitude of the increase was correlated with the size of EMG facilitation (Fig. 7A). Excitation of LC cells after OX-A microinjections preceded muscle-tone facilitation by an average 5.8 ± 0.9 s (n = 9). We used a regression analysis for estimating the numerical relationship between changes of integrated gastrocnemius EMG and ipsilateral LC unit firing rate after OX-A microinjections (Fig. 8A). The regression equation of EMG (%) on rate (%) after OX-A microinjections was EMG = 48.34 + 0.46Rate (SE = 26.09, 0.16; t = 2.80; P < 0.05; df = 14). The correlation coefficient between EMG and ipsilateral LC unit firing rate was 0.59 (n = 16, P < 0.05). One LC cell did not change firing frequency after OX-A microinjection.
|
|
The discharge rate of eight LC units was analyzed during OX-B microinjections into the fourth ventricle. All cells were excited by OX-B microinjections (177 ± 13%, n = 8, T = 0, P < 0.01), and their activity correlated with hindlimb muscle-tone facilitation (Figs. 7B and 8B). The increased firing frequency of LC units preceded the muscle-tone increase after OX-B microinjections by an average 6.2 ± 1.0 s (n = 8). The regression equation of EMG (%) on rate (%) after OX-B microinjections was EMG = 45.41 + 0.52Rate (SE = 26.59, 0.19; t = 2.83; P < 0.05; df = 14) and the correlation coefficient between these variables was 0.60 (n = 16, P < 0.05).
| |
DISCUSSION |
|---|
|
|
|---|
We found that microinjections of OX-A and -B in the vicinity of LC
increase LC unit activity and produce a correlated facilitation of
muscle tone in decerebrate rats. No difference was observed in the
effect of OX-A and -B on muscle tone and LC unit firing rate. Our data
concerning excitatory OX influences on LC neurons are consistent with
results obtained in rat brain slices. Intra- and extracellular
recordings revealed that OX-A applications evoked depolarization of LC
units and increased their firing frequency (Hagan et al.
1999
). In a similar manner, hypocretin-2 (OX-B) applications
depolarized all tested LC cells and increased their spontaneous rate.
Membrane depolarization persisted in the presence of tetrodotoxin,
indicating that the response to OX-B was synaptically mediated
(Horvath et al. 1999
; Ivanov and Aston-Jones
2000
).
Trivedi and co-authors (1998)
using in situ
hybridization with receptor subtype-specific oligonucleotide probes
reported that only OX1R were located in the LC.
These receptors are relatively selective for OX-A, whereas
OX2R is nonselective for OX-A and -B
(Sakurai et al. 1998
). OX-A fibers project widely in the
brain stem, and the LC receives the densest OX-A innervation
(Cutler et al. 1999
; Hagan et al. 1999
).
These data were complemented by studies that revealed a widespread
distribution of both OX-A and -B immunoreactive fibers in the rat brain
and in the LC (Date et al. 1999
). Horvath and
co-authors (1999)
using electron microscopy showed that all
TH-positive cells in the LC receive asymmetrical (excitatory) synaptic
contacts from multiple axons containing hypocretin-2. A specific
radioimmunoassay performed for OX-A and -B showed that OX-B
concentration was double OX-A level in the rat brain stem
(Mitsuma et al. 1999
, 2000
).
Electrophysiological and pharmacological studies indicate that LC units
with descending projections have a facilitatory action on spinal
motoneurons (Andre et al. 1995
; D'Ascanio et al.
1989
; Fung and Barnes 1981
; Fung et al.
1991
, 1994
; Rispoli et al. 1994
). Moreover,
noradrenergic LC neurons also may produce an indirect excitatory effect
on spinal motoneurons by inhibition of pontine cholinergic and
cholinoceptive neurons participating in descending muscle-tone
suppression (Horn et al. 1987
; Pompeiano et al.
1987
). LC units reduce their activity during non-REM sleep and
cease discharge for an extended period during REM sleep with its
associated muscle atonia (Hobson et al. 1975
;
Jacobs 1986
). It has been shown recently that a
significant decrease of REM sleep occurred after OX-A microinjections
into the LC in freely moving rats (Bourgin et al. 2000
).
Wu et al. (1999)
reported that LC neurons cease
discharge immediately before and throughout cataplexy periods in canine
narcoleptics. These results combined with our recent data showing a
correlation between LC activity and muscle tone (Kiyashchenko et
al. 1999
; Mileykovskiy et al. 2000
) indicate
that LC activity contributes to the regulation of muscle tone across
the sleep cycle and to the facilitation of motor activity during
waking. The current results lead us to hypothesize that the major
descending projections of the OX system to the LC facilitates muscle
tone, perhaps especially during emotionally linked movements with
correlated motor inhibition.
We have observed hindlimb muscle-tone inhibition as a result of OX-A
and -B microinjections into the PIA. The PIA is part of an inhibitory
brain stem-reticulospinal system hyperpolarizing spinal motoneurons
(Jankowska et al. 1968
; Siegel et al.
1991
; Takakusaki et al. 1994
). This pontine
region participates in induction of REM-sleep atonia (Chase and
Morales 1990
; Lai and Siegel 1990a
,b
; Sakai et al. 1979
) and causes cessation of discharge in
LC neurons during electrical stimulation (Mileykovskiy et al.
2000
). Neurons located in the mesencephalic locomotor region
and related to muscle-tone facilitation (Garcia-Rill and Skinner
1988
) are also inhibited by PIA electrical stimulation
(Mileykovskiy et al. 2000
). The PIA has a low OX fiber
innervation (Nambu et al. 1999
; Peyron et al.
1998
). However, this region is a very effective inhibitor of
muscle tone (Kohyama et al. 1998
; Lai and Siegel
1990a
,b
; Siegel et al. 1983
) and even a low
level of OX innervation of the PIA may be sufficient to trigger potent
reticulospinal inhibition.
We also propose that OXs may act on their presynaptic receptors located
on glutamatergic axons and modulate brain stem neuron activity by
presynaptic glutamatergic release as it was described for hypothalamic
cells in addition to their direct postsynaptic action (Van den
Pol et al. 1998
). The LC receives glutamatergic inputs from
nucleus paragigantocellularis (Ennis and Aston-Jones 1988
). Ultrastructural and intracellular studies have
indicated that glutamate may locally modulate activity in noradrenergic LC neurons through N-methyl-D-aspartate (NMDA)
and non-NMDA receptors (Luque et al. 1995
;
Sengoku et al. 1999
; Van Bockstaele and Colago 1996
). The PIA receives dense glutamatergic projections from
the mesencephalic reticular nucleus, the retrorubral nucleus, and the
ventral portion of the paralemniscal tegmental field (Lai et al.
1993
). Glutamate microinjections into the PIA evoked
muscle-tone suppression in decerebrate cats (Lai and Siegel
1991
). Ultrastructural studies of pontine nuclei revealed that
asymmetric glutamatergic synaptic contacts are located on dendrites,
neuronal somata and axons (Border and Mihailoff 1991
).
Our hypothesis that OXs may modulate brain stem neuron activity by
presynaptic glutamatergic release is supported by data about the
similar latency of muscle-tone facilitation and inhibition (50-120 s)
after injections of small doses of glutamate agonists into the
pontomedullary region (Lai and Siegel 1991
). The latency
of muscle-tone facilitation and LC unit firing rate increase (2-3 min)
after OX microinjections into fourth ventricle is presumably related to
the diffusion of drugs from the ventricle into the LC.
At present only two OX receptor types have been identified. However, the possibility that other OX receptor types exist has not yet been ruled out. Other receptors with a similar response to OX-A and -B could be responsible for the similar response profile to these ligands. Alternatively, the relative selectivity of these receptors may not be sufficient to discriminate between OX-A and -B when applied by microinjection.
We have recently shown that a massive loss of OX neurons is linked to
narcolepsy (Thannical et al. 2000
). The loss of OX input to the LC would reduce a major facilitatory drive to the LC. We hypothesize that a loss of this facilitatory input allows phasic motor
inhibition elicited by emotion to cause a loss of muscle tone
(cataplexy). In neurologically normal individuals, phasic OX release
prevents these losses of tone.
The role of OX in the control of both LC and PIA suggests that a
malfunction of this system can affect both motor facilitation and motor
inhibition. In this regard, it is interesting to note that many
narcoleptic patients not only experience sudden losses of muscle tone
in waking (cataplexy) but also have a pathological absence of muscle
atonia during REM sleep, producing the REM sleep behavior disorder
(Schenck and Mahowald 1992
). Malfunction of the OX
system may be responsible for both of these symptoms of narcolepsy.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by National Heart, Lung, and Blood Institute Grants HL-41370 and HL-60296 and by the Medical Research Service of the Department of Veterans Affairs.
| |
FOOTNOTES |
|---|
Address for reprint requests: J. M. Siegel, Dept. of Psychiatry, UCLA, Neurobiology Res. 151A3, VAMC, 16111 Plummer St., North Hills, CA 91343 (E-mail: JSiegel{at}ucla.edu).
Received 27 November 2000; accepted in final form 9 February 2001.
| |
REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
P. B. Schwarz, N. Yee, S. Mir, and J. H. Peever Noradrenaline triggers muscle tone by amplifying glutamate-driven excitation of somatic motoneurones in anaesthetized rats J. Physiol., December 1, 2008; 586(23): 5787 - 5802. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Thannickal, Y.-Y. Lai, and J. M. Siegel Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinson's disease Brain, January 1, 2008; 131(1): e87 - e87. [Full Text] [PDF] |
||||
![]() |
S. A. Deadwyler, L. Porrino, J. M. Siegel, and R. E. Hampson Systemic and Nasal Delivery of Orexin-A (Hypocretin-1) Reduces the Effects of Sleep Deprivation on Cognitive Performance in Nonhuman Primates J. Neurosci., December 26, 2007; 27(52): 14239 - 14247. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Stiasny-Kolster, S.-C. Clever, J. C. Moller, W. H. Oertel, and G. Mayer Olfactory dysfunction in patients with narcolepsy with and without REM sleep behaviour disorder Brain, February 1, 2007; 130(2): 442 - 449. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takakusaki, K. Takahashi, K. Saitoh, H. Harada, T. Okumura, Y. Kayama, and Y. Koyama Orexinergic projections to the cat midbrain mediate alternation of emotional behavioural states from locomotion to cataplexy J. Physiol., November 1, 2005; 568(3): 1003 - 1020. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. John, M.-F. Wu, N. T Maidment, H. A Lam, L. N Boehmer, M. Patton, and J. M Siegel Developmental changes in CSF hypocretin-1 (orexin-A) levels in normal and genetically narcoleptic Doberman pinschers J. Physiol., October 15, 2004; 560(2): 587 - 592. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Walling, D. J. Nutt, M. D. Lalies, and C. W. Harley Orexin-A Infusion in the Locus Ceruleus Triggers Norepinephrine (NE) Release and NE-Induced Long-Term Potentiation in the Dentate Gyrus J. Neurosci., August 25, 2004; 24(34): 7421 - 7426. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Peever, Y.-Y. Lai, and J. M. Siegel Excitatory Effects of Hypocretin-1 (Orexin-A) in the Trigeminal Motor Nucleus Are Reversed by NMDA Antagonism J Neurophysiol, May 1, 2003; 89(5): 2591 - 2600. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. John, M.-F. Wu, T. Kodama, and J. M Siegel Intravenously administered hypocretin-1 alters brain amino acid release: an in vivo microdialysis study in rats J. Physiol., April 15, 2003; 548(2): 557 - 562. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-F. Wu, J. John, N. Maidment, H. A. Lam, and J. M. Siegel Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2002; 283(5): R1079 - R1086. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. I. Kiyashchenko, B. Y. Mileykovskiy, N. Maidment, H. A. Lam, M.-F. Wu, J. John, J. Peever, and J. M. Siegel Release of Hypocretin (Orexin) during Waking and Sleep States J. Neurosci., July 1, 2002; 22(13): 5282 - 5286. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Xi, S. J. Fung, J. Yamuy, F. R. Morales, and M. H. Chase Induction of Active (REM) Sleep and Motor Inhibition by Hypocretin in the Nucleus Pontis Oralis of the Cat J Neurophysiol, June 1, 2002; 87(6): 2880 - 2888. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Y. Mileykovskiy, L. I. Kiyashchenko, and J. M. Siegel Muscle Tone Facilitation and Inhibition After Orexin-A (Hypocretin-1) Microinjections Into the Medial Medulla J Neurophysiol, May 1, 2002; 87(5): 2480 - 2489. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |